Placenta Growth Factor - Pipeline Review, H1 2020

April 2020 | 88 pages | ID: P022C9F168A4EN
Global Markets Direct

Abstracts

Placenta Growth Factor - Pipeline Review, H1 2020

SUMMARY

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 21 molecules. The latest report Placenta Growth Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 5 respectively.

Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Central Retinal Vein Occlusion, Choroidal Neovascularization, Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Corneal Neovascularization, Metastatic Colorectal Cancer, Myopia, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Retinal Vein Occlusion, Retinopathy, Retinopathy Of Prematurity and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Amgen Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cinnagen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Lupin Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KH-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2020: Bayer launches pre-filled syringe to administer eye medication Eylea in Europe
Feb 10, 2020: Bayer announces Phase III trials with new aflibercept 8mg formulation
Feb 10, 2020: Regeneron reports two-year diabetic retinopathy data of Eylea
Jan 23, 2020: Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea
Aug 13, 2019: Last trial OKed for Eylea to prevent blindness in premature infants
Aug 13, 2019: FDA approves Eylea (AFLIBERCEPT) prefilled syringe
Jun 21, 2019: Bayer initiates phase III trial of Aflibercept to prevent blindness in premature infants
May 22, 2019: Alteogen obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
May 13, 2019: Formycon provides update on FYB203
May 13, 2019: FDA Approves EYLEA (aflibercept) Injection for Diabetic Retinopathy
Apr 30, 2019: Watchful waiting reasonable for patients with Diabetic Macular Edema and good vision
Apr 02, 2019: LY09004 approved for clinical trials in China, Luye Pharma steps-up Global R&D Investment in Biopharma Medicines
Feb 28, 2019: Alteogen applies for P1 trial for Eylea biosimilar
Feb 09, 2019: One-year results from positive phase 3 EYLEA trial in diabetic retinopathy presented at Angiogenesis Symposium
Jan 21, 2019: New anti-VEGF agent shows promising durability
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Alteogen Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
Pipeline by Cinnagen Co, H1 2020
Pipeline by Clover Biopharmaceuticals, H1 2020
Pipeline by Coherus BioSciences Inc, H1 2020
Pipeline by Formycon AG, H1 2020
Pipeline by Gene Techno Science Co Ltd, H1 2020
Pipeline by Huons Global Co Ltd, H1 2020
Pipeline by i2 Pharmaceuticals Inc, H1 2020
Pipeline by Lupin Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Pipeline by PharmAbcine Inc, H1 2020
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pipeline by Samsung Bioepis Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Alteogen Inc
Amgen Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cinnagen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Lupin Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd